Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

Family-owned Boehringer Ingelheim, now Germany’s largest drugmaker by revenue, has reported positive growth in the first half ...

The total value of the deal exceeds $1bn for the first three targets, in addition to royalty payments based on net sales.

Boehringer Ingelheim partners with Re-Vana Therapeutics to innovate long-acting eye disease treatments, enhancing patient care and compliance.

Queens University spin-out Re-Vana Therapeutics has agreed a $1bn deal with biopharma giant Boehringer Ingelheim.

Boehringer Ingelheim and Re-Vana Therapeutics, a U.S. and UK based developer of ocular therapeutics and drug delivery ...

Ingelheim: Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK-based developer of ocular therapeutics and ocular drug ...